ProstaLund Financials
| PLUN Stock | SEK 9.00 2.00 28.57% |
ProstaLund |
Please note, the imprecision that can be found in ProstaLund's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of ProstaLund AB. Check ProstaLund's Beneish M Score to see the likelihood of ProstaLund's management manipulating its earnings.
ProstaLund Stock Summary
ProstaLund competes with Episurf Medical, Senzime AB, Acarix AS, and Scibase AB. ProstaLund AB develops, manufactures, and sells urological devices and treatments.| Instrument | Sweden Stock View All |
| Exchange | Stockholm Exchange |
| ISIN | SE0002372318 |
| Business Address | Scheelevgen 19, Lund, |
| Sector | Healthcare |
| Industry | Medical Care Facilities |
| Benchmark | Dow Jones Industrial |
| Website | prostalund.se |
| Phone | 46 46 12 09 08 |
| Currency | SEK - Swedish Kronor |
You should never invest in ProstaLund without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of ProstaLund Stock, because this is throwing your money away. Analyzing the key information contained in ProstaLund's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
ProstaLund Key Financial Ratios
ProstaLund's financial ratios allow both analysts and investors to convert raw data from ProstaLund's financial statements into concise, actionable information that can be used to evaluate the performance of ProstaLund over time and compare it to other companies across industries.| Return On Equity | -0.25 | |||
| Return On Asset | -0.13 | |||
| Beta | 0.84 |
ProstaLund Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining ProstaLund's current stock value. Our valuation model uses many indicators to compare ProstaLund value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across ProstaLund competition to find correlations between indicators driving ProstaLund's intrinsic value. More Info.ProstaLund AB is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the ProstaLund's earnings, one of the primary drivers of an investment's value.ProstaLund AB Systematic Risk
ProstaLund's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. ProstaLund volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on ProstaLund AB correlated with the market. If Beta is less than 0 ProstaLund generally moves in the opposite direction as compared to the market. If ProstaLund Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one ProstaLund AB is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of ProstaLund is generally in the same direction as the market. If Beta > 1 ProstaLund moves generally in the same direction as, but more than the movement of the benchmark.
ProstaLund December 27, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of ProstaLund help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of ProstaLund AB. We use our internally-developed statistical techniques to arrive at the intrinsic value of ProstaLund AB based on widely used predictive technical indicators. In general, we focus on analyzing ProstaLund Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build ProstaLund's daily price indicators and compare them against related drivers.
| Information Ratio | (0.14) | |||
| Maximum Drawdown | 34.93 | |||
| Value At Risk | (8.63) | |||
| Potential Upside | 5.61 |
Additional Tools for ProstaLund Stock Analysis
When running ProstaLund's price analysis, check to measure ProstaLund's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ProstaLund is operating at the current time. Most of ProstaLund's value examination focuses on studying past and present price action to predict the probability of ProstaLund's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ProstaLund's price. Additionally, you may evaluate how the addition of ProstaLund to your portfolios can decrease your overall portfolio volatility.